Acasti Pharma Inc. to Present at the ATVB 2010 Council of the American Heart Association
April 08 2010 - 7:30AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) and Acasti Pharma Inc. ("Acasti")
announce the acceptance for presentation of preclinical study
results at the council for Arteriosclerosis, Thrombosis and
Vascular Biology (ATVB) 2010 Scientific Sessions Meeting of the
American Heart Association to be held April 8-10 in San Francisco,
CA.
The results of the study entitled "CaPreTM, an Omega-3:
Phospholipid, Managing Dyslipidemia in Three Murine Phenotypes"
will be presented by Dr. Steven J. Adelman, Ph.D., FAHA,
CEO/Founder of Vascular Strategies LLC. This study, conducted in
collaboration with Professor Daniel Rader, University of
Pennsylvania School of Medicine, and Dr. Steven J. Adelman,
evaluates the mechanism of action of Acasti's prescription drug
candidate (omega-3 phospholipid "CaPreTM") for the treatment of
dyslipidemia and cardio-metabolic disorders.
CaPreTM was shown to be effective in beneficially modulating the
lipid profile of healthy and diseased mice with high cholesterol,
obesity and diabetes. CaPreā¢ significantly reduced triglycerides
(60%) and bad cholesterol - LDL (28%) while simultaneously
increasing good cholesterol - HDL (25%).
"We are all very pleased that our data has been accepted by the
American Heart Association, through a peer reviewed process,
allowing us to introduce Acasti in the medical scientific community
with our participation in the ATVB 2010 sessions" said Dr. Tina
Sampalis, President of Acasti Pharma Inc. "It is a great privilege
to work with distinguished scientists like Prof. Rader and Dr.
Adelman. This is the first of three studies we are working on
together, and we are looking forward to expanding to further
preclinical and clinical studies soon."
About Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the major
component of cell membranes and are essential for all vital cell
processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the
Company to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties
that are described from time to time in the Company's reports filed
with the Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Henri Harland, CEO
450-687-2262
h.harland@neptunebiotech.com
www.neptunebiotech.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024